[1] |
中华人民共和国国家卫生健康委员会. 新冠病毒疫苗接种技术指南(第一版). 中华临床感染病杂志, 2021, 14(2):89-90. doi: 10.3760/cma.j.issn.1674-2397.2021.02.002.
doi: 10.3760/cma.j.issn.1674-2397.2021.02.002
|
[2] |
中华医学会感染病学分会艾滋病丙型肝炎学组. 成人人类免疫缺陷病毒感染者新型冠状病毒疫苗接种专家建议. 中华内科杂志, 2021, 60(7):615-618. doi: 10.3760/cma.j.cn112138.20210403-00259.
doi: 10.3760/cma.j.cn112138.20210403-00259
|
[3] |
中华医学会感染病学分会, 中华医学会风湿病学分会. 特殊人群(慢性肝病、结核病和风湿免疫病患者)新型冠状病毒疫苗接种专家建议. 中华传染病杂志, 2021, 39(7):398-403. doi: 10.3760/cma.j.cn311365-20210507-00163.
doi: 10.3760/cma.j.cn311365-20210507-00163
|
[4] |
World Health Organization. Global Tuberculosis Report 2021. Geneva: World Health Organization, 2021.
|
[5] |
Fei H, Yinyin X, Hui C, et al. The impact of the COVID-19 epidemic on tuberculosis control in China. Lancet Reg Health West Pac, 2020, 3:100032. doi: 10.1016/j.lanwpc.2020.100032.
doi: 10.1016/j.lanwpc.2020.100032
|
[6] |
Cilloni L, Fu H, Vesga JF, et al. The potential impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis. EClinicalMedicine, 2020, 28:100603. doi: 10.1016/j.eclinm.2020.100603.
doi: 10.1016/j.eclinm.2020.100603
URL
|
[7] |
Wu Z, Chen J, Xia Z, et al. Impact of the COVID-19 pandemic on the detection of TB in Shanghai, China. Int J Tuberc Lung Dis, 2020, 24(10):1122-1124. doi: 10.5588/ijtld.20.0539.
doi: 10.5588/ijtld.20.0539
URL
|
[8] |
沈鑫, 沙巍, 刘剑君. 新型冠状病毒肺炎疫情对结核病防控的影响及对策. 中国防痨杂志, 2020, 42(6):544-548. doi: 10.3969/j.issn.1000-6621.2020.06.003.
doi: 10.3969/j.issn.1000-6621.2020.06.003
|
[9] |
Yeo C, Kaushal S, Yeo D. Enteric involvement of coronaviru-ses: is faecal-oral transmission of SARS-CoV-2 possible? Lancet Gastroenterol Hepatol, 2020, 5(4):335-337. doi: 10.1016/S2468-1253(20)30048-0.
doi: 10.1016/S2468-1253(20)30048-0
URL
|
[10] |
Wang Y, Wang Y, Chen Y, et al. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol, 2020, 92(6):568-576. doi: 10.1002/jmv.25748.
doi: 10.1002/jmv.25748
URL
|
[11] |
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 2020, 323(11):1061-1069. doi: 10.1001/jama.2020.1585.
doi: 10.1001/jama.2020.1585
URL
|
[12] |
Yang H, Lu S. COVID-19 and Tuberculosis. J Transl Int Med, 2020, 8(2):59-65. doi: 10.2478/jtim-2020-0010.
doi: 10.2478/jtim-2020-0010
URL
|
[13] |
Liu Y, Bi L, Chen Y, et al. Active or latent tuberculosis increases susceptibility to COVID-19 and disease severity[J/OL]. medRxiv, 2020[2021-09-27]. doi: 10.1101/2020.03.10.20033795. Online ahead of print.
doi: 10.1101/2020.03.10.20033795
|
[14] |
Ranzani OT, Hitchings MDT, Dorion M, et al. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. BMJ, 2021, 374:n2015. doi: 10.1136/bmj.n2015.
doi: 10.1136/bmj.n2015
|
[15] |
Tanriover MD, Dogˇanay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet, 2021, 398(10296):213-222. doi: 10.1016/S0140-6736(21)01429-X.
doi: 10.1016/S0140-6736(21)01429-X
URL
|
[16] |
Yang S, Li Y, Dai L, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomi-sed, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis, 2021, 21(8):1107-1119. doi: 10.1016/S1473-3099(21)00127-4.
doi: 10.1016/S1473-3099(21)00127-4
URL
|
[17] |
Wu S, Huang J, Zhang Z, et al. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Lancet Infect Dis, 2021: S1473-3099(21)00396-0. doi: 10.1016/S1473-3099(21)00396-0.
doi: 10.1016/S1473-3099(21)00396-0
|
[18] |
Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet, 2020, 396(10249):479-488. doi: 10.1016/S0140-6736(20)31605-6.
doi: 10.1016/S0140-6736(20)31605-6
URL
|
[19] |
Tadolini M, Codecasa LR, García-García JM, et al. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. Eur Respir J, 2020, 56(1):2001398. doi: 10.1183/13993003.01398-2020.
doi: 10.1183/13993003.01398-2020
URL
|